Clinical pharmacokinetics of parenterally administered danofloxacin in cattle.
Danofloxacin is a new fluoroquinolone antibacterial, developed specifically for veterinary use. Its in vitro activity and pharmacokinetic properties have been investigated to assess its potential for use in the therapy of respiratory disease in cattle. The minimum inhibitory concentration of danofloxacin against 90% (MIC90) of contemporary European and North American field isolates of Pasteurella haemolytica, Pasteurella multocida and Haemophilus somnus, the most important bacterial respiratory pathogens of cattle, was 0.125 micrograms/ml. The plasma and lung kinetics of danofloxacin following parenteral administration of 1.25 mg/kg were evaluated in two studies. Danofloxacin was rapidly absorbed following intramuscular and subcutaneous injection and bioavailability was virtually complete (101% and 94% respectively). Plasma concentration profiles of danofloxacin were similar for intramuscular and subcutaneous routes with no significant differences in the area under the plasma concentration-time curves (AUC) following one, three or five consecutive daily doses, although slightly higher peak plasma concentrations were achieved by the intramuscular route. Following intramuscular administration, the mean peak lung concentration of danofloxacin was 4.1 times greater than that of plasma. Similarly, the AUC for lung tissue was 3.7 times greater than that for plasma. These data indicate that danofloxacin should be particularly appropriate for the therapy of bacterial respiratory disease in cattle.
Giles
C J
CJ
Pfizer Central Research, Sandwich, Kent, UK.
Magonigle
R A
RA
Grimshaw
W T
WT
Tanner
A C
AC
Risk
J E
JE
Lynch
M J
MJ
Rice
J R
JR
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D001682:Biological Availability; D002417:Cattle / Q000378:metabolism*; D002418:Cattle Diseases / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006190:Haemophilus / Q000187:drug effects; D006207:Half-Life; D007273:Injections, Intramuscular / Q000662:veterinary; D007275:Injections, Intravenous / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D008168:Lung / Q000378:metabolism; D008297:Male; D016978:Mannheimia haemolytica / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D016979:Pasteurella multocida / Q000187:drug effects; D015363:Quinolones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D012141:Respiratory Tract Infections / Q000382:microbiology / Q000662:veterinary; D014018:Tissue Distribution
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C068581:danofloxacin